Skip to main content
All Posts By

adminpcb

Arian International and the CEI International Affairs will launch the 2nd edition of the European Proposal Writing Course

Arian Internacional -a company associated with Barcelona Science Park (PCB) and accredited by ICEX Spain Export and Investment– and the CEI International Affairs –affliated Center to the University of Barcelona in the diplomacy and international relations field– launch the 2nd edition of the European Proposal Writing Course, offering an Expert title, issued by the University of Barcelona (UB).

 

Read More

IRB Barcelona opens new laboratory focused on targeted protein degradation as a therapeutic tool

Scientist Cristina Mayor-Ruiz joins the Institute for Research in Biomedicine (IRB Barcelona) to lead the new Targeted Protein Degradation and Drug Discovery Lab. Along with the addition of this group, the Institute, based in the Barcelona Science Park, is also launching a Drug Screening Unit, thereby reflecting a clear commitment to speeding up the transfer of basic research to clinical practice.

 

Read More

Great success of the 13th IBEC Symposium “Bioengineering for Future & Precision Medicine”

The Institute for Bioengineering of Catalonia (IBEC), based in the Barcelona Science Park, organized from the 27th to the 28th October its 13th Symposium. The event, that this year took place for the first time online, was focused on “Bioengineering for Future & Precision Medicine”. With more than 400 registered attendees, the event also counted with contributions from top international speakers.

 

Read More

A project led by IBMB-CSIC tests molecules that stop the cytokine storm caused by SARS-CoV-2

A team of researchers led by Timothy Thomson’s group from the Barcelona Institute of Molecular Biology (IBMB-CSIC), based at the Barcelona Science Park, has developed a platform that allows to see in real-time if a drug inhibits the immune cellular response caused by SARS-CoV-2 infection. The project has the advantage that all the molecules being tested are previously known drugs and compounds that are used for other clinical indications. This would expedite the necessary procedures to propose, in due course, the use in patients with COVID-19.

 

Read More

PCB adds to the call led by SOMMa, ASEICA and AseBio to place R&D&I at the heart of the country strategy

The Barcelona Science Park joints the appeal, led by SOMMaASEICA and AseBio, which calls for long-term strategies aimed at promoting frontier science and business innovation. More than 40 leading organisations, scientific associations and innovative companies have signed a document that calls for Spain to reach and exceed 2.5% investment in R&D by 2027 and radically change its current economic model. This initiative aims to add and provide strategic solutions to the recent Pact for Science and Innovation that the Government has just announced.

 

Read More

BHV Partners settles in the Barcelona Science Park and closes a 500,000 euros investment round

BHV Partners, the first venture builder in the southern European health sector, has moved its headquarters to the Barcelona Science Park, and closes an investment round, raising half a million euros. In just over a year of history, the company, also based in Silicon Valley (San Francisco), has established itself as a leading driver in the biomedical innovation and entrepreneurship scene; it has three startups in its portfolio; has established several consulting contracts with companies and research centers, and is initiating an ambitious phase of national and international expansion.

 

Read More

Researchers reveal the evolutionary events leading to the creation of eukaryotic cells

A collaborative study between the groups of Toni Gabaldón, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona) and Berend Snel at the University of Utrecht, has reconstructed the evolutionary events leading to the creation of eukaryotic cells, the precursors to virtually all life you can see with the naked eye. The work, published in Nature Ecology & Evolution, reveals that The evolutionary timeline from simple bacterial cells to complex eukaryotic cells progressed differently than previously thought.

 

Read More

Researchers discover the adhesion mechanism of the bacterium that causes 40% of atypical pneumonias

Researchers from Institute of Molecular Biology of Barcelona (IBMB-CSIC) –based in the Barcelona Science Park– and the Institute for Natural Science and Technology at the University of Osaka, has succeeded in determining the three-dimensional structure of proteins by means of which the bacteria Mycoplasma pneumoniae –that cause 40% of atypical pneumonias– attaches itself to human cells and initiates infection. From the structure, this team of scientists have designed antibodies that decrease this adhesion capacity and opens the door to develop new therapies and vaccines against this pathogen.

 

Read More

Moirai Biodesign developes a diagnostic kit for the detection of sepsis in three hours

Moirai Biodesign, a biotech start-up based in the Barcelona Science Park, has developed a prototype ‘kit’ based on biosensors that analyzes a blood sample and identifiesthe most important sepsis-causing pathogens and their associated antibiotic resistances, at the point of care and directly from the patient’s blood, in just three hours, a process that usually requires up to 5 days of analysis in the laboratory. The company has just received a €75,000 grant through the Startup Capital financing line from ACCIÓ to  to set about the activities derived from the execution of the initial business plan. Its objective is to market this device in hospitals, once the validation phase is completed.The kit will allow identification 

Read More